146 related articles for article (PubMed ID: 9186297)
1. Effect of tolrestat, an aldose reductase inhibitor, on neutrophil respiratory burst activity in diabetic patients.
Ihm SH; Yoo HJ; Park SW; Park CJ
Metabolism; 1997 Jun; 46(6):634-8. PubMed ID: 9186297
[TBL] [Abstract][Full Text] [Related]
2. Nicotinamide effects oxidative burst activity of neutrophils in patients with poorly controlled type 2 diabetes mellitus.
Osar Z; Samanci T; Demirel GY; Damci T; Ilkova H
Exp Diabesity Res; 2004; 5(2):155-62. PubMed ID: 15203886
[TBL] [Abstract][Full Text] [Related]
3. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
[TBL] [Abstract][Full Text] [Related]
4. The influence of aldose reductase on the oxidative burst in diabetic neutrophils.
Tebbs SE; Lumbwe CM; Tesfaye S; Gonzalez AM; Wilson RM
Diabetes Res Clin Pract; 1992 Feb; 15(2):121-9. PubMed ID: 1314160
[TBL] [Abstract][Full Text] [Related]
5. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients.
Bravi MC; Pietrangeli P; Laurenti O; Basili S; Cassone-Faldetta M; Ferri C; De Mattia G
Metabolism; 1997 Oct; 46(10):1194-8. PubMed ID: 9322806
[TBL] [Abstract][Full Text] [Related]
6. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
[TBL] [Abstract][Full Text] [Related]
7. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
Cotter MA; Cameron NE; Hohman TC
J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
[TBL] [Abstract][Full Text] [Related]
8. In vitro inhibition of glucose phosphorylation by an aldose-reductase inhibitor (Tolrestat) in some non-insulin-sensitive rabbit tissues.
Iannello S; Cavaleri A; Camuto M; Belfiore F
J Diabetes Complications; 1999; 13(2):68-73. PubMed ID: 10432169
[TBL] [Abstract][Full Text] [Related]
9. A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group.
Macleod AF; Boulton AJ; Owens DR; Van Rooy P; Van Gerven JM; Macrury S; Scarpello JH; Segers O; Heller SR; Van Der Veen EA
Diabete Metab; 1992; 18(1):14-20. PubMed ID: 1563531
[TBL] [Abstract][Full Text] [Related]
10. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
Boland OM; Blackwell CC; Clarke BF; Ewing DJ
Diabetes; 1993 Feb; 42(2):336-40. PubMed ID: 8425670
[TBL] [Abstract][Full Text] [Related]
11. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
[TBL] [Abstract][Full Text] [Related]
12. Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.
McCaleb ML; McKean ML; Hohman TC; Laver N; Robison WG
Diabetologia; 1991 Oct; 34(10):695-701. PubMed ID: 1959701
[TBL] [Abstract][Full Text] [Related]
13. [Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?].
Daniele E; Coco MP
Clin Ter; 1995 Dec; 146(12):793-99. PubMed ID: 8681499
[TBL] [Abstract][Full Text] [Related]
14. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy.
Passariello N; Sepe J; Marrazzo G; De Cicco A; Peluso A; Pisano MC; Sgambato S; Tesauro P; D'Onofrio F
Diabetes Care; 1993 May; 16(5):789-95. PubMed ID: 8495620
[TBL] [Abstract][Full Text] [Related]
15. Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion.
McAuliffe AV; Brooks BA; Fisher EJ; Molyneaux LM; Yue DK
Nephron; 1998 Nov; 80(3):277-84. PubMed ID: 9807036
[TBL] [Abstract][Full Text] [Related]
16. Effects of glucose and SNK-860, an aldose reductase inhibitor, on the polyol pathway and chemiluminescence response of human neutrophils in vitro.
Kawamura T; Suzuki K; Matsumae H; Sano T; Sakamoto N; Hotta N
Diabet Med; 1995 May; 12(5):392-6. PubMed ID: 7648800
[TBL] [Abstract][Full Text] [Related]
17. Effect of aldose reductase inhibition on glutathione redox status in erythrocytes of diabetic patients.
De Mattia G; Laurenti O; Bravi C; Ghiselli A; Iuliano L; Balsano F
Metabolism; 1994 Aug; 43(8):965-8. PubMed ID: 8052153
[TBL] [Abstract][Full Text] [Related]
18. Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
Hayashi R; Hayakawa N; Makino M; Nagata M; Kakizawa H; Uchimura K; Hamada M; Aono T; Fujita T; Shinohara R; Nagasaka A; Itoh M
Diabetes Care; 1998 Apr; 21(4):672-3. PubMed ID: 9571366
[No Abstract] [Full Text] [Related]
19. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy.
Boulton AJ; Levin S; Comstock J
Diabetologia; 1990 Jul; 33(7):431-7. PubMed ID: 2119323
[TBL] [Abstract][Full Text] [Related]
20. No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients.
Hamada Y; Hammon K; Raskin P
J Diabetes Complications; 1992; 6(2):111-5. PubMed ID: 1611134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
